补中益气汤与PD-L1免疫治疗潜在药物相互作用的同系小鼠模型评价
该研究依据FDA指南,在C57BL/6小鼠CMT-167同系模型中评价补中益气汤与抗PD-L1抗体的药物相互作用。结果显示补中益气汤未改变抗PD-L1抗体的药代动力学特征,提示两者联合治疗非小细胞肺癌可能是安全选择,但需临床研究证实。
要点
- 补中益气汤未改变抗PD-L1抗体的药代动力学特征。
- 补中益气汤与阿替利珠单抗联合可能为NSCLC安全治疗选项。
- 该结论基于小鼠模型,需临床研究进一步确认。
核心结论
- 补中益气汤与抗PD-L1抗体联合未出现药代动力学层面的药物相互作用。
- 研究提示补中益气汤联合阿替利珠单抗治疗非小细胞肺癌可能是安全选择。
研究设计与样本
- 依据FDA指南开展体内药物相互作用研究,使用C57BL/6小鼠CMT-167同系肿瘤模型。
- 检测抗体浓度以评价药代动力学相互作用,并测定疗效与免疫应答相关生物标志物。
主要发现
- 在补中益气汤存在下,抗PD-L1抗体的药代动力学特征未发生改变。
临床怎么用
- 提示补中益气汤与PD-L1抑制剂联合时无需基于药代动力学相互作用调整抗体用药。
局限性
- 结论来自同系小鼠模型,需临床研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Atezolizumab (a PD-L1 inhibitor) has shown remarkable efficacy and tolerability in various cancer types. Despite its efficacy and safety, atezolizumab monotherapy has limitations, such as acquired resistance and adverse events. Bojungikki-tang (BJIKT) is an herbal decoction widely prescribed in Asian countries and used to treat cancer-related symptoms including fatigue, appetite loss, gastrointestinal disorders, and other side effects from cancer therapy. Due to its immunomodulatory effects, Bojungikki-tang has been investigated as a combined treatment with anticancer agents. We evaluated the potential drug-drug interaction (DDI) between Bojungikki-tang and the anti-PD-L1 antibody based on the Food and Drug Administration (FDA) guidelines. In the study, we conducted an in vivo drug-drug interaction study using a syngeneic mouse model of CMT-167 in C57BL/6. We then determined the antibody concentrations to evaluate the pharmacokinetic (PK) drug-drug interaction and measured variable biomarkers related to therapeutic efficacy and immune response. The pharmacodynamic (PD) drug-drug interaction study investigated changes in response between anti-PD-L1 antibody monotherapy and combination therapy. Using the pharmacokinetic and pharmacodynamic data, we conducted a statistical analysis to assess drug-drug interaction potential. In the presence of Bojungikki-tang, the pharmacokinetic characteristics of the anti-PD-L1 antibody were not changed. This study suggested that combination treatment with Bojungikki-tang and atezolizumab is a safe treatment option for non-small cell lung cancer. Clinical studies are warranted to confirm this finding.
引用
- Yang SY, Yi JM, Chun J, et al. Evaluation of the potential herb-drug interaction between Bojungikki-tang and PD-L1 immunotherapy in a syngeneic mouse model. Front Pharmacol. 2023. PMID: 37274110. doi:10.3389/fphar.2023.1181263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。